|
|
 |
|
Viewing report
|
|
|
|
Cancer Vaccines: Measuring Market Potential
Arrowhead Publishers, Oct 2004, Pages: 233
This brand new report published in October 2004 provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the context of the disease areas they are attempting to penetrate and include: melanoma, prostate cancer, colorectal cancer, lung cancer, breast cancer, and pancreatic cancer.
There are currently over twenty Phase III trials ongoing for various indications and new approvals may come as early as 2005. The value of the market for cancer vaccines has the potential to reach $6 billion by 2010.
This report is designed to provide the information, insight and analysis key to an understanding of how cancer vaccines will impact the biotech and pharmaceutical marketplace. Those in the field of cancer therapy and cancer vaccines will want to read this report in order to better understand where and how vaccines will make a difference in future cancer therapy.
This 232-page report:
- Gauges the potential of key vaccine products nearing commercialization.
- Analyzes the results of key clinical trials as a means of determining future success in the market.
- Forecasts financial growth of the cancer vaccine market through 2010.
- Assesses the competition from cytotoxics and other biologics in six key cancer markets.
- Provides valuable data concerning patient populations, survival rates, and global epidemiology
- Identifies and discusses trends and issues that will have a significant impact on the cancer vaccine market.
- Profiles the leading companies in the field and provides valuable information and analysis concerning their lead vaccine candidates.
|
|
|
|
